WHO WE ARE
UK leader focused on the research, cultivation,
manufacturing and supply of breakthrough cannabis-based medicines.

AT A GLANCE

100,000 sq ft UK based GMP approved facility comprising a laboratory and indoor hydroponic grow facility

One of the first licenced by the UK regulators and MHRA to produce GMP high-THC medicinal cannabis

MHRA (conditionally) approved clinical trial evaluating the use of cannabis medicines for the management of chronic pain

First-mover advantage to capture large UK opportunity, in a market with significant barriers to entry

£20 million of funding received to date to support execution of growth strategy

Publicly listed on London Stock Exchange (AIM) and the second pharmaceutical cannabis business on the world’s leading growth market since GW Pharma (acquired for $7bn in 2021)

OUR FACILITY
UK’s leading cannabis cultivation and drug development facility
Celadon has a 100,000 sq ft licenced facility based in the West Midlands in the UK. It is an EU-GMP facility with indoor hydroponic cultivation of high-THC cannabis flower, API extraction and an R&D lab for its drug development programme.
The facility has had substantial investment in it and has involved four years of close cooperation with UK regulators and the MHRA to build to EU-GMP standards and the highest level of security.
The facility is being built in three phases:
Phase 1: completed in 2021 with five indoor cultivation rooms, API extraction and R&D lab.
Phase 2: significant addition of indoor cultivation capacity, aiming to be operational in Q1 2023.
Phase 3: further expansion of cultivation and manufacturing capacity, with work targeted in 2024-25.
At full capacity, the facility could produce around 9 tonnes of product.





OUR MISSION
& VALUES



Celadon’s mission is to improve quality of life for patients most in need by developing breakthrough cannabis-based medicines



BOARD & MANAGEMENT
The Board

Alexander Anton
Alexander is an experienced AIM director and entrepreneur. Alexander is the former chairman and latterly a non-executive director of Victoria PLC, retiring from that role in 2019. He was Chairman of Summerway Capital Plc from October 2018 to January 2021. Alexander was chairman of The Queen’s Club from 2005-2007 and led the members’ buy out from the Lawn Tennis Association for £35 million in 2007. He is also the founder of Fraser Real Estate and Legacy Portfolio, businesses focused on complex leasehold portfolios.
Chairman

James Short
James is the founder and CEO of Celadon. James has had a successful track record in the construction industry and then in the renewable energy sector. He co-founded the waste to energy business Bio-Gen Power Ltd and sold stakes to Ener-G Holdings PLC in 2007 and to FTSE 100 company International Power in 2008. He sold the company in 2010.
Subsequently, James commissioned the feasibility study and obtained planning permission for the development of the £984 million 1,500 megawatt combined cycle gas turbine power plant at Thorpe Marsh in North Doncaster in partnership with Acorn Power and GE. In 2014, he sold the development to GE.
CEO & Founder

Jonathan Turner
Jonathan qualified as a Chartered Accountant in 2003 with the Institute of Chartered Accountants of England and Wales and an Associate Member of the Association of Corporate Treasurers in 2013. Jonathan has a degree in Physics from the University of Oxford.
Jonathan started his career as a tax advisor with Smith & Williamson in London where he provided tax advisory and compliance services to a range of clients from listed groups to owner managed businesses. When he qualified Jonathan, moved to Ernst & Young, originally joining the Banking & Capital Markets team before spending 6 years with the International Tax Services Group where he advised listed businesses on international expansion, acquisition structuring and financing.
In 2010, Jonathan joined Synergy Health plc as Head of Tax & Treasury - later also becoming the Group Company Secretary and a member of the Senior Executive Board. Synergy Health plc was a FTSE250 business providing clinical sterilisation services to hospitals and the medical device sector amongst others, and was acquired by STERIS plc (a NYSE listed provider of infection prevention and procedural surgical products and services for £1.4bn in 2015. In 2017, Jonathan joined Oxford Instruments plc, a FTSE 250 provider of high technology products, systems and tools to leading industrial companies and scientific research communities as Divisional Finance Director for the NanoScience and Magnetic Resonance Divisions, and became Group Director of Accounting, Tax & Treasury in 2020.
Chief Financial Officer

Robert Barr
Robbie is an experienced operator and director having spent the majority of his executive career with Vodafone PLC where he held senior executive positions, including group financial controller. Robbie is a Senior Advisor to OMERS Private Equity and Infrastructure in Europe and a Non-Executive Director of Associated British Ports Holdings, Chairman of Vue International, the cinema group, and a member of the supervisory committee of rail wagon leasing company VTG AG.
Robbie was formerly executive chairman of Four Seasons Health Care from 2014 to 2018 and of Odeon & UCI Cinemas from 2012 to 2016. From 2009 to 2015 he was a managing director of the private equity firm Terra Firma Capital Partners.
Senior Independent NED

Elizabeth Shanahan
Liz is currently a non-executive director of AIM-listed Inspiration Healthcare Group plc and a former non-executive director of UDG Healthcare plc, a company that was listed on the London Stock Exchange and a constituent of the FTSE 250 up until its £2.8 billion takeover, which completed in August 2021.
Liz is a life sciences entrepreneur with extensive experience advising leading global pharmaceutical and healthcare organisations on their communications. Until 2014, she was Global Head of Healthcare & Lifesciences at the NYSE-listed management consultancy, FTI Consulting Inc., who had in 2007 acquired the communications business, Santé Communications, which she founded in 1995. Liz is a Trustee of CW+, the charitable arm of Chelsea & Westminster Foundation Trust Hospital in London and a member of the organisation’s Innovations Advisory Board.
Independent NED

David Firth
David is a Fellow of the Institute of Chartered Accountants in England and Wales and a highly experienced Plc board member. He is a non-executive director of Parity Group Plc, an IT services and consultancy business, and chairman of its Remuneration and Audit Committees. David is also a non-executive director and Audit Committee Chairman of Best of the Best plc, an organiser of weekly competitions to win cars and other luxury prizes, and a non-executive director and chairman of the Audit Committee of i-Nexus Global Plc, a strategy execution software company.
Previously he was the finance director of Penna Consulting plc from 1999 to 2016. David has held a number of board positions in public companies over the past 30 years across various sectors including HR consultancy and recruitment, IT services, financial markets, motor retailing and advertising.
Independent NED

Dr Steven Hajioff
Steve has been a leader and innovator in healthcare and health policy for thirty years. He was the Chairman of the Representative Body of the British Medical Association (BMA) from 2010 to 2013 and has worked as a Medical Director or Chief Medical Officer in several organisations including Bupa Health Dialog, Totally PLC, Pain Management Solutions Ltd and The Knowde Group.
He previously advised NHS England on specialized services, including rare disease, orphan drugs and low-volume high cost procedures and has been an adviser to the National Institute for Health and Care.
Excellence (NICE) in a range of capacities since 2012. He is currently a member of their Quality Standards Advisory Committee.
He was, until recently, a Director of Public Health and a member of the Governing Body of a Clinical Commissioning Group in west London. Steve runs his own consultancy business and specialises in healthcare market access and reimbursement, clinical opportunity analysis and health policy.
Steve is currently the Chief Medical Officer at Sana Life sciences and is a scientific adviser to Phytome Life Sciences. He is also a Senior Lecturer at Imperial College London. He was formerly a member of the Medical Ethics Committee of the British Medical Association; one of the most influential bodies in UK clinical ethics.
In June 2015, the British Medical Association awarded Steve their highest honour, the Gold Medal for Distinguished Merit.
Independent NED
Senior Leadership Team

Arthur Wakeley
Experienced strategy consultant at McKinsey, with wide ranging experience across strategy, growth, digital innovation, and business building. Previously M&A investment banking at Lazard.
Managing Director

Iqbal Gill
25 years of experience in the natural products, pharmaceutical, biotechnology and chemical industries. 5+ years of extensive R&D experience in cannabinoids, especially formulation and delivery.
Chief Scientific Officer
Founders

Paul Allen
Co-Founder